Lee, JY Park, YK Seo, SH So, IS Chung, HK Yang, BS Lee, SJ Park, H Lee, YS 2024-01-21T11:37:54Z 2024-01-21T11:37:54Z 2021-09-05 2001-11 0365-6233 https://pubs.kist.re.kr/handle/201004/140069 The 4-anilinoquinazoline PD 153035 (1) is a potential antitumor agent which acts by inhibiting tyrosine kinase activity of epidermal growth factor receptor (EFGR) via competitive binding at the ATP site of enzyme. A series of cyclic analogues of PD 153035 bearing the 1,4-dioxane ring was prepared by reaction of 6-chloro derivative 5 with several aniline nucleophiles. These were evaluated for their ability to inhibit the EGFR kinase and the growth of primary human tumor cell cultures. All of the new 4-anilinoquinazolines exhibited less potency than PD 153035 against EGFR kinase. However, compounds 2b, 2c, 2e, 2g, and 2h showed higher inhibitory activities than PD 153035 against the growth of A431 tumor cell line. The compound 2b containing 3-chloroaniline ring was as potent as PD 153035 against EGFR kinase and showed about 5.4-fold better potency than PD153035 in the inhibition of growth of A431 cell line with good selectivity. English WILEY-V C H VERLAG GMBH 1,4-dioxane-fused 4-anilinoquinazoline as inhibitors of epidermal growth factor receptor kinase Article 10.1002/1521-4184(200112)334:11<357::AID-ARDP357>3.0.CO;2-Q 1 ARCHIV DER PHARMAZIE, v.334, no.11, pp.357 - 360 ARCHIV DER PHARMAZIE 334 11 357 360 N scie scopus 000173080100004 2-s2.0-0035666237 Chemistry, Medicinal Chemistry, Multidisciplinary Pharmacology & Pharmacy Pharmacology & Pharmacy Chemistry Article TYROSINE KINASE BINDING-SITE DOMAIN EGFR tyrosine kinases 4-anilinoquinazolines A431 cell antitumor agent 1,4-dioxane